Clinical trial NCT01452971: A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer
Official title: A Study of the Interaction Between Tumor Susceptibility Gene GNMT and Lung Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung Cancer
Keywords: tumor susceptibility gene
glycine N-methyltransferase (GNMT)
polycyclic aromatic hydrocarbons (PAHs)
lung cancer
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2011-10-17
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: primary care clinic

Brief summary: Environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) were reviewed as the major risk factors for lung cancer development. In this proposal, the investigators collected fifteen kinds of major PAHs and the investigators would like to perform the following studies:

1. Study the gene expression and subcellular localization of GNMT in the normal-tumor tissue pairs of lung cancer patients.
2. Study the associations of the polymorphisms of GNMT in lung cancer patients and the susceptibility to lung cancer;
3. To assess the allelic loss at GNMT and determined the LOH rate of GNMT in the normal-tumor tissue pairs of lung cancer patients.
4. Study the associations of the copy number variation (CNV) of GNMT and the susceptibility to lung cancer;
5. Study the interaction between GNMT and polycyclic aromatic hydrocarbons (PAHs) in lung cancer cell lines.

Detailed description: Multi-functional protein Glycine N-methyltransferase (GNMT, EC2.1.1.20, localized to chromosome 6p12), affects genetic stability by a) regulating the ratio of S-adenosylmethionine (SAM) to S-adenosylhomocystine (SAH) and b) binding to folate. Based on the following observations, GNMT is classified as a tumor susceptibility gene: a) diminished GNMT expression levels in both human hepatocellular carcinoma (HCC) cell lines and tissues; b) genotypic analyses of several human GNMT gene polymorphisms showed a loss of heterozygosity in 36-47% of the genetic markers in HCC tissues and also related to the susceptibility of prostate cancer; c) GNMT binds to environmental carcinogens such as benzo(a)pyrene (BaP) and aflatoxin B1 (AFB1) and protect the liver cells by inhibiting DNA-adduct formation.

Environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) were reviewed as the major risk factors for lung cancer development. In this proposal, the investigators collected fifteen kinds of major PAHs and would like to perform the following studies:

1. Study the gene expression and subcellular localization of GNMT in the normal-tumor tissue pairs of lung cancer patients.
2. Study the associations of the polymorphisms of GNMT in lung cancer patients and the susceptibility to lung cancer;
3. To assess the allelic loss at GNMT and determined the LOH rate of GNMT in the normal-tumor tissue pairs of lung cancer patients.
4. Study the associations of the copy number variation (CNV) of GNMT and the susceptibility to lung cancer;
5. Study the interaction between GNMT and polycyclic aromatic hydrocarbons (PAHs) in lung cancer cell lines.

So far, the investigators have analyzed the gene expression of GNMT in the normal-tumor tissue pairs of some lung cancer patients. The investigators also analyzed the interaction between the GNMT and some PAHs using lung cancer cell lines. These data are helpful to clarify the susceptibility of lung cancer patients with the gene expression in GNMT.

This study is helpful in elucidating the role of GNMT plays in the tumorigenesis of lung cancer which may have important implications in the development of strategies for the prevention, diagnosis and treatment of lung cancer and other types of cancer.

Eligibility criteria: Inclusion Criteria:

* Participant is a lung cancer patient.

Exclusion Criteria:

* Participant is under 18 years old.
* Participant is not a lung cancer patient.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: